Blog

mNEXSPIKE becomes Moderna’s third FDA-approved product

CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).^[1]

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA’s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.”

The FDA’s approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna’s original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.

In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company’s approved respiratory syncytial virus (RSV) vaccine.

mRNA-1283 is under review with regulators in multiple markets around the world.

About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna.

INDICATION
mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are:

• 65 years of age and older, or

• 12 years through 64 years of age at high risk for severe COVID-19.

Vaccination with mNEXSPIKE may not protect all people who receive the vaccine.

IMPORTANT SAFETY INFORMATION

You should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines.

What are the risks of mNEXSPIKE?
There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:

• Trouble breathing

• Swelling of your face and throat

• A fast heartbeat

• A rash all over your body

• Dizziness and weakness

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine:

• Chest pain

• Shortness of breath

• Feelings of having a fast-beating, fluttering, or pounding heart

Side effects that have been reported in clinical trials with mNEXSPIKE include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever

Tell your vaccination provider about all of your medical conditions, including if you:

• have any allergies

• had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

• have a fever

• have a bleeding disorder or are on a blood thinner

• are immunocompromised or are on a medicine that affects your immune system

• are pregnant or plan to become pregnant

• are breastfeeding

• have received any other COVID-19 vaccine

• have ever fainted in association with an injection

These may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

Please click for mNEXSPIKE Full Prescribing Information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna’s respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

View the original press release on ACCESS Newswire

ORLANDO, FL / ACCESS Newswire / May 30, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and FatPipe, Inc. (Nasdaq:FATN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 31, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• NXL: https://www.redchip.com/assets/access/nxl_access

• FATN: https://www.redchip.com/assets/access/fatn_access

In an exclusive interview, Nexalin CEO Mark White appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries – conditions that affect millions but have limited effective treatments – positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537 billion by 2030.

In an exclusive interview, Dr. Ragula Bhaskar, CEO of FatPipe, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is transforming enterprise connectivity through its patented, software-defined networking technologies. With a product suite spanning SD-WAN, Secure Access Service Edge (SASE), and Network Monitoring Services (NMS), FatPipe enables over 2,500 customers – including government agencies, financial institutions, and healthcare providers – to unify, secure, and optimize their networks across cloud, hybrid, and on-premise environments. Dr. Bhaskar highlights FatPipe’s robust financial performance, including $17.9 million in revenue and $4.4 million in net income for fiscal 2024, and outlines the company’s growth strategy focused on global expansion, product innovation, and deepening its high-margin, subscription-based revenue model. Positioned at the intersection of three multi-billion-dollar markets and operating as a “Rule of 40” business, FatPipe offers investors a compelling blend of profitability, scalability, and exposure to the accelerating digital infrastructure megatrend.

NXL and FATN are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

About FatPipe, Inc.

FatPipe pioneered the concept of software-defined wide area networking (SD-WAN) and hybrid WANs that eliminate the need for hardware and software or cooperation from ISPs and allows companies and service providers to control multi-link network traffic. FatPipe currently has 12 U.S. patents related to multipath, software-defined networking. FatPipe products are sold by 200+ resellers worldwide. For more information, visit www.fatpipeinc.com. Follow us on X @FatPipe_Inc.

To learn more, visit www.fatpipeinc.com or contact sales321@fatpipeinc.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip’s products and services, please visit:

https://www.redchip.com/corporate/investor_relations

“Discovering Tomorrow’s Blue Chips Today”™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire

Clear Start Tax Explains How the IRS Can Legally Withhold a Portion of Your Social Security and What Retirees Can Do About It

IRVINE, CA / ACCESS Newswire / May 30, 2025 / Many retirees believe that once they stop working, they’re no longer at risk of IRS enforcement. But according to Clear Start Tax, a leading tax resolution firm, that’s far from true. The IRS can and does garnish Social Security benefits for unpaid tax debt-leaving many seniors with less money to cover essential expenses.

The IRS’s Federal Payment Levy Program (FPLP) allows the agency to automatically deduct a portion of a taxpayer’s Social Security income if back taxes are owed. And while the program does follow a formal notice process, many seniors are caught off guard when their monthly benefits are suddenly reduced without warning.

How Social Security Garnishment Works

If a taxpayer has unpaid IRS debt and fails to resolve it, the IRS may initiate garnishment through the FPLP. This allows the agency to levy up to 15% of monthly Social Security benefits-without needing a court order.

“Many retirees live on fixed incomes, and even a small reduction can have a major impact,” said the Head of Client Solutions at Clear Start Tax. “We often work with clients who didn’t even know the IRS could touch their Social Security until it happened.”

How Seniors End Up Facing IRS Collection in Retirement

Many seniors assume their financial responsibilities with the IRS ended when they stopped working-but that’s not always the case. In fact, certain oversights or unresolved tax issues from years past can follow retirees well into their later years, triggering garnishment even when Social Security is their only source of income.

According to Clear Start Tax, seniors may be more vulnerable to enforcement if they:

• Have unpaid IRS balances from earlier working years

• Missed filings after retirement

• Never entered into a formal payment or settlement agreement

• Ignored IRS notices due to confusion or declining health

• Relied on Social Security as their sole or primary income

How Retirees Can Resolve IRS Debt Without Losing Benefits

The IRS offers formal resolution options for qualifying taxpayers-even those already receiving Social Security. Clear Start Tax helps seniors stop or prevent garnishment through:

• Installment Agreements – Set up manageable monthly payments to stop enforcement

• Currently Not Collectible (CNC) status – Temporarily pause collections for those with financial hardship

• Offer in Compromise (OIC) – Settle debt for less than owed based on financial capacity

• Penalty Abatement – Reduce or remove penalties that have accumulated over time

“If we can intervene early-even after garnishment has begun-there’s often a path to stop it,” added the Head of Client Solutions. “Seniors deserve financial peace in retirement, not unexpected collection actions.”

How Clear Start Tax Supports Seniors With IRS Debt

Clear Start Tax has worked with retirees across the U.S. to resolve long-standing IRS debt, avoid collections, and protect Social Security income. The firm provides:

• Expert IRS negotiation and case management

• Help with unfiled returns and back balances

• Personalized strategies based on fixed income

• Compassionate guidance for seniors and caregivers navigating tax stress

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?
Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

NORTH YORK, ON / ACCESS Newswire / May 30, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTC PINK:ZTSTF) announces Q3 2025 revenues of $2,105,297, a slight increase over the immediate proceeding quarter, but a decline from the record $2,625,282 reported for Q3 2024. Revenues for the nine months ended March 2025 were $6,205,665 as compared to $6,964,685 in the prior year.

While managing through headwinds mentioned in previous quarterly commentary, the Company takes some solace in the fact that revenues for the nine-month period remain almost 59% ahead of March 2023, that gross margin percentages have been maintained, that liquidity has been further enhanced, and that cash flows from operations remain strong.

Financial Highlights		Three months ended
(in thousands of dollars, except per share amounts)		Mar 31 2025				Mar 31 2024
Revenue			2,105				2,625
Gross Margin			834				1,124
Gross Margin as a % of Revenue			39.6	%			42.8	%
EBITDA			424				788
Net Income			256				531
Basic Net Income per share			0.007				0.017
Operating Cash Flow			392				676

Financial Position		As at
(in thousands of dollars)		Mar 31 2025				Jun 30 2024
Cash			3,867				2,776
Working Capital			4,648				3,593
Long-term Debt			73				121
Shareholders’ Equity			5,550				4,497

The Company’s management and Board of Directors is continually evaluating capital allocation strategies including M&A opportunities. While no such strategic transaction is imminent, management also recognized that an opportunity exists to take advantage of what it perceives to be an under-valuation of its own securities. An NCIB commenced on April 1, 2025, and to date the Company has repurchased 296,500 common shares.

Steve Smith, CEO commented, “Our ability to adapt to the shifting environment is reflected in our consistent operating margin and compelling cash generation. There are subtle indications that demand may soon start to increase, however we remain diligent, due to the uncertainties spawned by new and possible international tariffs. Ultimately, we continue to be centered on operational execution and driving shareholder value.”

About ZTEST Electronics Inc.
ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corporation (“Permatech”), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech’s offering includes Printed Circuit Board (PCB) Assembly, Materials Management and Testing services. Permatech operates from an ISO 9001:2015 certified facility in North York, Ontario, Canada. Permatech is a contract assembler of complex circuit boards, serving customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial, Trucking, Wearables and Consumer Electronics markets. It specializes in servicing customers who are looking for high yield and require high quality and rapid-turnaround on low and mid-volume production of high complexity products.

For more information contact: Steve Smith, CEO (604) 837-3751 email: steves@ztest.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.com).

SOURCE: ZTEST Electronics Inc.

View the original press release on ACCESS Newswire

INDIANAPOLIS, IN / ACCESS Newswire / May 30, 2025 / Two Arrive Points™ – smart mailboxes that anchor a pioneering autonomous delivery network – have been delivered to Arrive AI (NASDAQ:ARAI) headquarters and will be installed at Hancock Regional Hospital early next week. The installation will enable autonomous delivery of biospecimens from the hospital’s cancer center to nurses’ stations as part of an initial two-year partnership between Arrive AI and Hancock Health, which represents Arrive AI’s first revenue generating deployment. The collaboration will exploit the transformative potential of asynchronous robotic automation for medical deliveries within hospitals, aiming to unlock significant cost savings through technological advancements and operational efficiencies using Arrive AI technology.

These spiffy new units will match the branding on the robot that Arrive AI is deploying in this groundbreaking use-case. Testing of routes within the hospital will begin once installation is complete.

The regional hospital, a member of the Mayo Clinic Care Network, and Arrive AI announced their partnership launch on May 19, 2025. This partnership places Hancock Health at the forefront of autonomous medical logistics, with potential applications across its broader network of more than 30 locations in East Central Indiana.

“This rollout creates a milestone moment for our young company. We’re so eager to see these operations begin,” said Dan O’Toole, CEO of Arrive AI. “The eyes of healthcare worldwide will be watching this significant moment.”

Hancock Health has identified operational inefficiencies that include having medical personnel make numerous daily trips between its clinics and hospital lab to deliver specimens. Those trips pull staff from critical duties, delay lab results and increase labor costs. The multi-phase commitment with Arrive AI will showcase how cutting edge, asynchronous technology is set to change the healthcare landscape in a seismic way.

The phased rollout of the initiative includes: a comprehensive readiness evaluation; the installation of robotic technology at the hospital’s Sue Ann Wortman Cancer Center and laboratory; the development of optimized delivery routes; the expansion of technology deployment to off-campus locations; and the introduction of drone-based transport for time-sensitive and off-site medical deliveries. Each phase will incorporate Arrive Points, providing a standardized and secure interface for all chain-of-custody transfers.

Arrive AI will leverage the insights gained from this deployment to develop a scalable framework for integrating ground robotics, courier networks, and drones across Hancock Health’s entire network. Arrive AI will quarterback the design, execution, and optimization of this integrated system, ensuring regulatory compliance, operational feasibility, and a validated return on investment. Key strategies for enhancing efficiency and reliability include:

• Deploying drones for urgent and off-campus transport needs.

-30-

About Arrive AI: Arrive AI’s patented last mile (ALM) platform enables drone-based and human mail delivery to and from a physical smart mailbox, while providing tracking data, smart logistics alerts, and advanced chain of custody controls to secure the last-mile delivery for all shippers, delivery services, and autonomous delivery networks. Arrive AI makes the exchange of goods between people, robots, and drones frictionless, efficient, and convenient through artificial intelligence, autonomous technology, and interoperability with smart devices including doorbells, lighting and security systems. Learn more details about the company’s patents here. See videos of the smart mailbox in action here.

Media contact: Cheryl Reed, media@arriveai.com

Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

About Hancock Health: Hancock Health, a Mayo Clinic Care Network Member, is a full-service healthcare network serving East Central Indiana at Hancock Regional Hospital and more than 30 other locations to ensure convenience to high quality care. A member of the Suburban Health Organization (SHO) and partner to Peyton Manning Children’s Hospital, Hancock Health believes in the power of partnerships to lower costs and improve health outcomes for patients. Hancock Health’s expert physicians have access to Mayo Clinic’s research, diagnostic, and treatment resources across specialties including cancer care, women’s health, primary care, wellness, emergency medicine, and more – all with the goal of improving health outcomes and making health possible for East Central Indiana. Media Contact: Claire Hunter, claire@pencemediagroup.com

Cautionary Note Regarding Forward Looking Statements 

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” ,”optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov . Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

Epique Realty COO and Co-Founder’s Leadership Triumphs

HOUSTON, TX / ACCESS Newswire / May 30, 2025 / In a landmark moment for innovation in real estate, Epique Realty is happy to announce that its own Christopher Miller, Chief Operating Officer and Co-Founder,has been honored as one of Inman’s 2025 Future Leaders in Real Estate in the prestigious Founders/Entrepreneurs category. This coveted award celebrates the next generation of visionaries forging new paths, introducing transformative ideas, and making significant contributions to the evolution of real estate.

The 2025 Future Leaders in Real Estate Award spotlights emerging talents who have demonstrated exceptional leadership skills and a firm commitment to pushing the envelope in the real estate industry. Emily Paquette, CEO of Inman, commented, “Inman is celebrating the 2025 class of rising stars who have distinguished themselves early in their careers. The 2025 Future Leaders in Real Estate truly embody the potential to be the next generation of industry titans.”

COO Christopher Miller, a driving force behind Epique Realty’s meteoric rise, has been instrumental in redefining the brokerage model. His agent-first philosophy and relentless pursuit of innovation have helped catapult Epique from 300 agents in early 2024 to an astonishing family of nearly 4,000 agents across 36 states in 2025. This formidable growth is a direct testament to Epique’s revolutionary approach, offering extraordinary benefits and advanced technology free to agents that empower and fuel agent success.

Speaking about the honor, COO Christopher Miller expressed gratitude and excitement for this milestone. “This recognition truly belongs to the entire Epique family. At the heart of what we do is a simple belief-that empowering agents with the right tools, support, and opportunities leads to success. This award reflects the innovation, hard work, and community that our agents and team have built together on our journey to reshape the industry for the better!” Christopher’s philosophy of accessibility and heartfelt connection to the agent community has made Epique a trailblazer in the industry.

Echoing this sentiment, CEO and Co-Founder Josh Miller remarked, “Epique is built on a revolutionary idea-that the brokerage should work for the agent, not the other way around. Christopher’s visionary leadership and unshakable belief in our mission have been instrumental in our incredible growth. He’s shown that by putting people first, we can truly reshape the industry. Chris leads with heart and an unyielding dedication to our agents. He saw what real estate could be – a place where agents are truly valued, supported, and empowered to build incredible careers and lives. This Inman award is a well-deserved acknowledgment of his relentless drive to make that vision a reality. He’s not just building a company; he’s building a legacy for every single member of our Epique family.”

CFO and Co-Founder, Janice Delcid, highlighted Christopher’s strategic impact on the company’s revolutionary model: “Christopher’s innovative spirit and operational expertise have been pivotal in architecting an ecosystem where agents thrive. His ability to foresee industry shifts and implement supportive structures, like our incomparable suite of free benefits unheard of in our industry and advanced technology, ensures our agents are always ahead of the curve. This award underscores his exceptional leadership in building a brokerage that is not only experiencing explosive growth but is also financially empowering for our agents. We’re incredibly proud to see his contributions recognized at such a prestigious level.”

At Epique Realty, the mission has always been clear: put agents first. This philosophy is woven into the fabric of the company, offering exceptional support, including personal accessibility to leadership, deep mentorship opportunities, and a culture where agents are treated like family. By integrating AI-powered tools, ensuring operational efficiencies, and providing a wealth of resources at no extra cost, Epique empowers its agents to reach unprecedented levels of success. Initiatives like Epique Cares and NEMO, which Christopher championed, further showcase the company’s commitment to blending heart and strategy, mobilizing aid for communities in need.

Epique Realty is experiencing amazing growth while it spearheads a revolution in the real estate industry. The company’s agent-first, agent-empowerment approach is setting new standards, proving that a brokerage can prioritize its people and achieve phenomenal progress. As Christopher Miller’s leadership demonstrates, Epique is more than a business; it’s a movement, a family, and the future of real estate.

About Epique Realty

Epique Realty is a trailblazing, agent-owned real estate brokerage committed to empowering its agents through extraordinary support, state-of-the-art and AI tech and a comprehensive suite of free resources and benefits that fuel agent success. With a rapidly expanding presence across the nation, Epique Realty is redefining industry norms by fostering a culture of collaboration, innovation, and shared success, truly making it a family where agents thrive and succeed. #BeEpique

Barbara Simpson | PR and Communications
281-773-7842 | Barbara@EpiqueRealty.com

https://www.instagram.com/epiquerealty/
https://www.facebook.com/epiquerealty
https://www.linkedin.com/company/epique-realty/mycompany/
https://www.youtube.com/@epiquerealty

SOURCE: Epique Realty

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / May 29, 2025 / New to The Street, the nationally recognized business television series, proudly presents an exclusive original broadcast spotlighting IMG Academy, the world leader in sports education. The feature will air Saturday, May 31 at 6:30 PM ET on Bloomberg Television as sponsored programming.

This televised special provides a rare inside look at IMG Academy’s elite campus, transformative development model, and the innovative tools preparing the next generation of leaders both on and off the field. The segment will highlight how IMG Academy integrates world-class athletic training, rigorous academics, and personalized development to shape future collegiate athletes and high-character individuals.

IMG Academy Highlights:

• Top 3 finalist for the World’s Best School Prize – “Supporting Healthy Lives” (only U.S. finalist in the category)

• 100% college acceptance rate for the Class of 2024

  • 10 student-athletes accepted to Ivy League institutions

  • 20 student-athletes admitted to top 25 U.S. universities

  • 3 student-athletes accepted to U.S. Military Academies

  • 332 student-athletes committed to NCAA Division I, II, III, and NAIA programs

• 4.35M+ athlete profile views on NCSA by college coaches in 2024

• 40,000+ college coaches on the NCSA recruiting platform

• 31,000+ athlete college commitments in 2024

• 14 partnerships with national sports governing bodies

Strategic Brand Alliances

IMG Academy’s mission is reinforced through strategic partnerships with top global brands that share its commitment to performance, innovation, and excellence. These include: Under Armour, Gatorade, Therabody, Merrill, Uni, Dunlop, and NTT Sonority.

Cross-Platform Distribution

The Bloomberg Television premiere will be amplified across New to The Street‘s media ecosystem, including distribution to its 2.5M+ YouTube subscribers, syndication across major social platforms, and iconic billboard exposure throughout Times Square and the NYC Financial District.

About IMG Academy
IMG Academy is the world’s leading sports education brand, offering a holistic model that prepares student-athletes to succeed in sport, college, and life. Based in Bradenton, Florida, IMG Academy delivers a comprehensive suite of development programs through its state-of-the-art boarding school and sports camps. Its innovative online platform, IMG Academy+, provides personalized coaching with a focus on personal growth through athletic performance. Through its NCSA recruiting network, IMG Academy also connects student-athletes with more than 40,000 college coaches, offering unparalleled access, tools, and guidance to navigate the collegiate recruitment process. To learn more, visit www.imgacademy.com.

About New to The Street
New to The Street is a nationally syndicated business media platform known for long-form interviews with founders, executives, and public company leaders. Broadcasting weekly across Fox Business and Bloomberg Television as sponsored programming, the show reaches over 219 million U.S. households. With a digital footprint that includes 2.5+ million YouTube subscribers, 700K+ social followers, and the most powerful billboard presence in Times Square and NYC’s Financial District, New to The Street is the only financial media brand delivering high-impact exposure across broadcast, digital, social, and out-of-home channels.

Media Contact:
Monica Brennan
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling its intra-quarter webcast and investor update call to June 17, 2025, from June 3, 2025, to allow for the implementation of a reverse stock split that will become effective on June 2, 2025.

Prepared remarks by members of the Applied DNA management team will be followed by a live question-and-answer session with the Company’s sell-side analysts and institutional investors.

Webcast and Conference Call Date & Time: Tuesday, June 17 @ 4:30 p.m. Eastern Time

Dial In:

• Domestic callers (toll-free): 844-887-9402

• International callers: 412-317-6798

• Canadian callers (toll-free): 866-605-3852

• Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Ky09znsL

A replay of the conference call will be available for 7 days following the conclusion of the call:

• Replay for domestic callers (toll-free): 877-344-7529, replay access code 3446494

• Replay for international callers: 412-317-0088, replay access code 3446494

• Replay for Canadian callers (toll-free): 855-669-9658, replay access code 3446494

An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the ‘Company Presentations‘ page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the ‘Company Events‘ page.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using the polymerase chain reaction (“PCR”) to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase (“RNAP”) for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

For additional information:

Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Web: https://investors.adnas.com/

SOURCE: Applied DNA Sciences, Inc.

View the original press release on ACCESS Newswire

ORLANDO, FL / ACCESS Newswire / May 29, 2025 / Unusual Machines, Inc. (NYSE American:UMAC) (“Unusual Machines” or the “Company”), a leading U.S. manufacturer of drone components, today announced that CEO Allan Evans has been invited to present at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” presented by Maxim Group LLC, on Tuesday, June 3rd – Thursday, June 5th at 10:00 a.m. EDT.

Unusual Machines will be taking part in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow.” The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. In Maxim’s 2025 Virtual Tech Conference, we will explore how emerging growth companies are expanding their use of Quantum Computing and Artificial Intelligence (AI) to position themselves for the future. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business.

Unusual Machines presentation is scheduled for Tuesday, June 3^rd at 10am EDT.

This conference will be live on M-Vest. To attend, sign up to become an M-Vest member.

Click here to learn more and reserve your seat

About Maxim Group LLC

Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ.

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot e-commerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit www.unusualmachines.com.

Investor Contact:
CS Investor Relations
investors@unusualmachines.com
917-633-8980

SOURCE: Unusual Machines, Inc.

View the original press release on ACCESS Newswire